info@birdgroup.be

Login

Papers

Eur J Cancer . 2023 Jul;187:36-57. doi: 10.1016/j.ejca.2023.03.025. Epub 2023 Mar 25.
Position statement on the management of the immune checkpoint inhibitor-induced colitis via multidisciplinary modified Delphi consensus

Journal of Crohn's and Colitis, 27 September 2022, jjac145
What are the Unmet Needs and Most Relevant Treatment Outcomes According to Patients with Infammatory Bowel Disease? A Qualitative Patient Preference Study

Gastroenterology. 2022 Aug 5;S0016-5085(22)00828-9
Effect of 5-hydroxytryptophan on fatigue in quiescent inflammatory bowel disease: a randomized controlled trial

Inflamm Bowel Dis . 2022 Jan 15;izab339.
The Multiple Waves of COVID-19 in Patients With Inflammatory Bowel Disease: A Temporal Trend Analysis

Journal of Crohn's and Colitis, jjac009, 25 january 2022
Introduction of subcutaneous infliximab CT-P13 and vedolizumab in clinical practice: a multi-stakeholder position statement highlighting the need for post-marketing studies

DIAMOND Platform from the Belgian IBD Research; Development (BIRD) group

Gastroenterology 2019;157(4): 997-1006.e6. Epub 2019 Jun 5.
Vedolizumab Induces Endoscopic and Histologic Remission in Patients with Crohn's Disease.

Acta Gastroenterol Belg., Jul-Sep 2019;82(3):365-372.
Ulcerative colitis treatment: an insight into daily clinical practice

Clinical Gastroenterology and Hepatology, 2020 Jul; 18(8):1704-1718.
Systematic Review and External Validation of Prediction Models Based on Symptoms and Biomarkers for Identifying Endoscopic Activity in Crohn's Disease

1
2
3
4
5
6
7
›